The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Letter
Public
AHA expresses support for the Maternal Health Accountability Act (S. 1112), as amended and passed by the Senate Health, Education, Labor and Pensions Committee…
Advisory
Member
This AHA Legislative Advisory offers a detailed summary of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for…
Case Studies
Public
Northern Maine Medical Center – Fort Kent, Maine
Letter
Public
AHA letter to the US Senate supporting Amendment #3787 to address ‘out-of-control cost’ of prescription drugs.
Letter
Public
AHA comments on the Department of Health and Human Services’ Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Advisory
Member
On June 6, President Trump signed into law the VA Maintaining Internal Systems and Strengthening Integrated Outside Networks Act of 2018, (S. 2372), known as…